Glenview Trust Co Takes $3.07 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Glenview Trust Co bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 3,968 shares of the biopharmaceutical company’s stock, valued at approximately $3,066,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Empowered Funds LLC lifted its position in shares of Regeneron Pharmaceuticals by 117.5% in the 2nd quarter. Empowered Funds LLC now owns 33,963 shares of the biopharmaceutical company’s stock worth $21,177,000 after acquiring an additional 18,345 shares during the period. Coastal Bridge Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 6.1% during the second quarter. Coastal Bridge Advisors LLC now owns 1,614 shares of the biopharmaceutical company’s stock valued at $1,006,000 after purchasing an additional 93 shares during the period. Jefferies Financial Group Inc. raised its stake in shares of Regeneron Pharmaceuticals by 46.4% in the second quarter. Jefferies Financial Group Inc. now owns 19,740 shares of the biopharmaceutical company’s stock valued at $12,309,000 after purchasing an additional 6,259 shares in the last quarter. MASTERINVEST Kapitalanlage GmbH raised its stake in shares of Regeneron Pharmaceuticals by 1.3% in the second quarter. MASTERINVEST Kapitalanlage GmbH now owns 2,772 shares of the biopharmaceutical company’s stock valued at $1,728,000 after purchasing an additional 35 shares in the last quarter. Finally, Proficio Capital Partners LLC bought a new position in Regeneron Pharmaceuticals in the second quarter worth $567,000. 83.31% of the stock is currently owned by institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $320,000.00. Following the transaction, the director owned 603 shares of the company’s stock, valued at $482,400. The trade was a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 1,400 shares of company stock worth $1,090,030. 6.97% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Piper Sandler cut their price target on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research note on Thursday, July 9th. Sanford C. Bernstein raised Regeneron Pharmaceuticals to a “hold” rating in a report on Wednesday, July 29th. BMO Capital Markets cut their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Wells Fargo & Company upped their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. Finally, Leerink Partners increased their price objective on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a research note on Monday, August 17th. Fifteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $800.36.

Regeneron Pharmaceuticals Trading Down 1.7%

REGN opened at $794.19 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The company has a market cap of $81.77 billion, a price-to-earnings ratio of 19.63, a price-to-earnings-growth ratio of 1.37 and a beta of 0.22. The firm has a 50 day simple moving average of $717.52 and a 200 day simple moving average of $718.38. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $847.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the firm earned $12.81 earnings per share. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone growth. In a 56-week Phase 3 trial, the approved dose reduced disease-related bone formation, giving Regeneron a new commercial opportunity and strengthening its rare-disease pipeline. However, the small patient population likely limits the drug’s near-term earnings contribution. Can Regeneron’s Rare-Disease Win Move the Earnings Needle?
• Neutral Sentiment: An investor letter highlighted Regeneron’s response to mixed results from its melanoma drug trials, including adjustments to its development strategy. The update offers limited new information but underscores the importance of replacing potential value lost from the failed program. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action related to disclosures surrounding Regeneron’s failed Phase 3 melanoma trial. The failure reportedly erased approximately $11 billion in market capitalization and prompted allegations that investors were misled about the program. The repeated notices, all citing a September 14, 2026 lead-plaintiff deadline, add reputational and potential litigation-cost risks, although they do not represent a finding of wrongdoing. Regeneron Securities Fraud Class Action Filed Faruqi Shareholder Notice

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.